Pomerantz Appointed Lead Counsel in Y-mAbs Therapeutics Securities Litigation

On April 4, 2023, U.S. District Judge Jesse M. Furman, of the Southern District of New York, appointed Pomerantz LLP as Lead Counsel on behalf of Omar Miramontes – the Lead Plaintiff, and the class, in In re Y-mAbs Therapeutics, Inc. Sec. Lig., 23-cv-431 (S.D.N.Y.). This securities class action alleges that Y-mAbs Therapeutics, Inc. misled investors regarding the efficacy of Omburtamab and the regulatory and commercial prospects of the drug. Y-mAbs is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics and medicines for the treatment of cancer. Omburtamab is the Company’s lead product candidate for the treatment of neuroblastoma in the central nervous system or leptomeninges…